rapidli
spread
viral
pandem
caus
influenza
requir
rapid
action
fastest
way
combat
challeng
repurpos
exist
drug
antivir
therapeut
first
show
human
organonachip
organ
chip
microfluid
cultur
devic
line
highli
differenti
primari
human
lung
airway
epithelium
cultur
airliquid
interfac
fed
continu
medium
flow
use
model
viru
entri
replic
straindepend
virul
host
cytokin
product
recruit
circul
immun
cell
respons
infect
influenza
well
effect
exist
novel
therapeut
airway
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
use
assess
inhibitori
activ
clinic
approv
drug
chloroquin
arbidol
toremifen
clomiphen
amodiaquin
verapamil
amiodaron
found
inhibit
infect
viral
pseudoparticl
express
spike
protein
human
cell
other
recent
show
suppress
infect
nativ
vero
cell
chip
technolog
may
use
conjunct
exist
rapid
cellbas
screen
assay
studi
human
diseas
pathogenesi
expedit
drug
repurpos
biothreat
crise
caus
pandem
virus
increas
incid
potenti
pandem
virus
influenza
mer
sar
requir
develop
new
preclin
approach
acceler
develop
effect
therapeut
prophylact
rapid
way
confront
pandem
challeng
would
repurpos
exist
drug
approv
medic
applic
antivir
therapeut
clinician
around
world
attempt
pandem
current
approach
haphazard
result
equivoc
result
regard
drug
efficaci
possibl
toxic
risk
case
chloroquin
thu
great
need
attack
problem
authorfund
right
reserv
reus
allow
without
permiss
systemat
way
recogn
potenti
danger
unforeseen
pandem
defens
advanc
research
project
agenc
darpa
nation
institut
health
nih
fund
work
laboratori
explor
whether
human
organonachip
organ
chip
microfluid
cultur
technolog
might
help
confront
potenti
biothreat
challeng
previous
show
organ
chip
recapitul
human
organ
physiolog
diseas
state
therapeut
respons
clinic
relev
drug
pharmacokinet
pk
exposur
high
fidel
show
human
lung
airway
chip
may
use
model
human
lung
respons
viral
infect
vitro
concert
higher
throughput
cellbas
assay
identifi
exist
approv
drug
potenti
repurpos
treat
prevent
spread
viral
pandem
caus
influenza
well
viru
caus
current
crisi
infect
respiratori
virus
current
studi
use
cultur
establish
cell
line
primari
tissuederiv
human
cell
human
organoid
ex
vivo
human
lung
tissu
cultur
anim
model
howev
preclin
model
signific
limit
supplementari
tabl
exampl
cultur
cell
line
often
need
supplement
exogen
proteas
enabl
viral
propag
wherea
endogen
proteas
natur
express
airway
epithelium
exert
crucial
action
human
cell
line
even
human
cell
grown
convent
cultur
exhibit
highli
differenti
tissu
structur
function
seen
live
human
organ
explant
cultur
human
respiratori
tract
tissu
circumv
limit
avail
limit
viabil
maintain
short
time
day
human
lung
organoid
provid
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
function
lung
epithelium
allow
cultur
airliquid
interfac
ali
model
physiolog
relev
organlevel
featur
lung
mucu
layer
format
mucociliari
clearanc
crosstalk
epithelium
endothelium
recruit
circul
immun
cell
play
key
role
host
respons
infect
respiratori
virus
moreov
cultur
model
drug
studi
carri
static
condit
predict
human
respons
clinic
relev
dynam
drug
exposur
pk
profil
importantli
anim
model
current
use
benchmark
valid
therapeut
natur
host
influenza
viru
infect
possibl
commonli
exhibit
differ
system
clinic
manifest
human
husbandri
requir
also
complex
expens
ethic
use
nonhuman
primat
garner
increas
concern
even
nih
thu
urgent
need
altern
preclin
model
better
mimic
human
lung
respons
infect
potenti
pandem
respiratori
virus
abil
recapitul
human
organlevel
physiolog
pathophysiolog
human
lung
chip
offer
potenti
solut
studi
initi
prior
pandem
began
explor
whether
organ
chip
technolog
use
creat
preclin
model
influenza
viru
infect
pathogenesi
effect
mimic
human
lung
airway
epitheli
endotheli
immun
cell
respons
vitro
human
airway
chip
microfluid
devic
contain
two
parallel
microchannel
separ
extracellular
matrixco
porou
membran
primari
human
lung
airway
basal
stem
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cell
grown
airliquid
interfac
ali
one
side
membran
airway
channel
tissu
layer
interfac
primari
human
lung
endothelium
grown
opposit
side
membran
expos
continu
fluid
flow
within
parallel
vascular
channel
fig
devic
support
differenti
lung
airway
basal
stem
cell
mucociliari
pseudostratifi
epithelium
proport
airwayspecif
cell
type
ciliat
cell
mucusproduc
goblet
cell
club
cell
basal
cell
fig
well
establish
continu
tight
junction
cilia
fig
permeabl
barrier
properti
level
mucu
product
fig
c
similar
observ
human
airway
vivo
well
prior
airway
chip
studi
use
membran
smaller
pore
vs
diamet
use
permit
immun
cell
transmigr
underli
human
pulmonari
microvascular
endothelium
also
form
continu
planar
cell
monolay
cell
link
vecadherin
contain
adheren
junction
fig
vivo
importantli
highli
differenti
airway
epithelium
airway
chip
express
higher
level
multipl
serin
proteas
includ
compar
mdck
cell
often
use
studi
influenza
infect
vitro
fig
proteas
essenti
activ
propag
influenza
virus
vivo
addit
differenti
airway
cell
ali
onchip
accompani
larg
increas
protein
fig
mrna
express
level
receptor
angiotensin
convert
fig
e
well
proteas
fig
also
requir
infect
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
channel
microfluid
chip
mimic
vivo
infect
airborn
influenza
fig
realtim
fluoresc
microscop
analysi
confirm
viru
infect
human
airway
epitheli
cell
fig
supplementari
movi
accompani
damag
epithelium
includ
disrupt
tight
junction
loss
apic
cilia
fig
compromis
barrier
function
fig
significantli
less
infect
detect
undifferenti
airway
basal
epithelium
prior
cultur
ali
onchip
detect
direct
infect
endothelium
viru
fig
interestingli
howev
influenza
infect
led
disrupt
lung
endothelium
onchip
evidenc
loss
vecadherin
contain
adheren
junction
fig
fold
increas
viral
titer
hour
highli
differenti
human
lung
airway
epithelium
onchip
fig
notabl
viru
strain
exhibit
greater
replic
effici
viru
strain
wsn
fig
caus
barrier
function
damag
fig
cilia
loss
fig
replic
find
infecti
virul
caus
sever
clinic
symptom
human
donortodonor
variabl
minim
studi
term
sensit
influenza
infect
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
similar
viral
infect
obtain
chip
deriv
differ
healthi
epitheli
cell
donor
fig
site
infect
airway
epithelium
contribut
significantli
influenza
pathogenesi
lung
howev
studi
easili
exist
preclin
model
primari
human
neutrophil
perfus
vascular
channel
airway
chip
infect
observ
recruit
circul
immun
cell
apic
surfac
activ
lung
endothelium
within
minut
fig
top
supplementari
movi
follow
transmigr
neutrophil
endothelium
ecmcoat
pore
interven
membran
airway
epithelium
hour
fig
bottom
neutrophil
target
influenza
nucleoprotein
np
posit
infect
airway
cell
fig
induc
coalesc
cluster
decreas
size
time
result
clearanc
virus
evidenc
disappear
gfpposit
cell
period
day
fig
bottom
consist
abil
viru
induc
stronger
inflamm
rel
vivo
also
stimul
neutrophil
recruit
onchip
fig
neutrophil
infiltr
epithelium
significantli
decreas
viral
titer
onchip
fig
consist
protect
role
neutrophil
provid
clear
viru
vivo
infect
also
accompani
increas
secret
variou
inflammatori
cytokin
chemokin
includ
rant
could
easili
measur
effluent
vascular
channel
fig
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
variat
secret
proinflammatori
mediat
human
lung
airway
may
contribut
differ
pathogenesi
observ
differ
influenza
viru
strain
analysi
cytokin
level
drive
cytokin
storm
help
clinician
assess
diseas
sever
thu
compar
innat
immun
respons
human
airway
chip
infect
three
patientderiv
influenza
viru
strain
differ
virul
chip
infect
virus
known
produc
sever
clinic
symptom
patient
found
also
stimul
product
higher
level
cytokin
chemokin
virul
induc
highest
concentr
fig
result
mirror
clinic
find
patient
infect
increas
serum
concentr
inflammatori
factor
rel
significantli
contribut
diseas
pathogenesi
explor
whether
airway
chip
use
evalu
efficaci
potenti
antivir
therapeut
firstli
test
oseltamivir
tamiflu
antiinfluenza
drug
use
wide
clinic
oseltamivir
metabol
liver
releas
oseltamivir
acid
vivo
introduc
activ
metabolit
vascular
channel
airway
chip
infect
viru
mimick
blood
level
oral
administr
oseltamivir
effici
inhibit
influenza
replic
fig
prevent
virusinduc
compromis
barrier
function
fig
disrupt
epitheli
tight
junction
fig
decreas
product
multipl
cytokin
chemokin
onchip
fig
thu
airway
chip
faith
replic
effect
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
oseltamivir
previous
observ
human
suggest
may
serv
use
preclin
model
evalu
potenti
therapi
virusinduc
human
lung
infect
preclin
set
given
host
serin
proteas
human
airway
epitheli
cell
play
critic
role
influenza
viru
propag
express
significantli
elev
differenti
airway
chip
fig
f
explor
whether
exist
approv
drug
inhibit
serin
proteas
could
suppress
infect
deliv
airway
channel
influenzainfect
chip
ie
mimic
intratrach
deliveri
aerosol
nebul
lavag
studi
reveal
two
clinic
use
anticoagul
drug
nafamostat
fig
trasylol
fig
significantli
reduc
influenza
titer
onchip
explor
nafamostat
action
reveal
protect
airway
barrier
function
fig
tight
junction
integr
fig
decreas
product
cytokin
chemokin
fig
nafamostat
proteas
inhibitor
appear
act
effici
block
serin
proteasemedi
enzymat
cleavag
influenza
viral
protein
subunit
fig
ad
nafamostat
oseltamivir
differ
time
point
influenza
infect
onchip
nafamostat
oseltamivir
exhibit
prophylact
therapeut
effect
fig
howev
therapeut
effect
oseltamivir
detect
administ
within
h
postinfect
fig
consist
observ
oseltamivir
recommend
clinic
use
within
day
influenza
infect
one
import
limit
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
antivir
therapeut
nafamostat
also
exhibit
inhibitori
effect
h
time
period
fig
impress
howev
combin
administr
nafamostat
oseltamivir
exert
potent
antiinfluenza
effect
combin
regimen
abl
doubl
oseltamivir
treatment
time
window
hour
fig
given
faith
recapitul
human
lung
respons
influenza
infect
observ
quickli
pivot
effort
focu
infect
learn
emerg
pandem
allevi
safeti
concern
immedi
initi
work
laboratori
design
pseudoparticl
contain
spike
protein
assembl
onto
luciferas
report
genecarri
retrovir
core
particl
base
genom
sequenc
releas
januari
confirm
pseudovirion
contain
full
length
cleav
version
protein
detect
use
western
blot
analysi
antibodi
fig
previous
shown
pseudotyp
virus
pseudotyp
viral
particl
faith
reflect
key
aspect
nativ
entri
host
cell
via
bind
receptor
thu
use
test
potenti
entri
inhibitor
vesicular
stomat
viru
vsv
gp
protein
pseudoparticl
vsvpp
also
gener
use
parallel
studi
exclud
toxic
nonspecif
effect
entri
inhibitor
success
gener
confirm
effici
infect
cell
human
liver
cell
line
commonli
use
studi
infect
sar
virus
wherea
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
control
pseudoparticl
without
spike
protein
infect
fig
use
cell
model
well
format
test
effect
multipl
drug
approv
fda
medic
applic
includ
chloroquin
arbidol
toremifen
clomiphen
amodiaquin
verapamil
amiodaron
drug
chosen
base
hypothesi
might
broadspectrum
antivir
activ
shown
inhibit
infect
virus
influenza
sar
ebola
drug
demonstr
dosedepend
inhibit
entri
cell
ad
simultan
viru
cultur
hour
fig
without
produc
detect
cell
toxic
model
fig
result
promis
howev
cell
deriv
human
liver
tumor
wherea
preferenti
target
lung
human
establish
cell
line
express
low
level
express
thu
clinic
relev
find
clear
therefor
introduc
air
channel
highli
differenti
human
lung
airway
chip
mimic
human
infect
airborn
high
level
viral
pol
gene
encod
detect
lung
airway
epitheli
cell
chip
infect
within
hour
control
chip
inocul
pseudoparticl
without
spike
protein
fig
abil
effici
infect
human
airway
chip
consist
find
highli
differenti
lung
cell
express
high
level
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
receptor
well
fig
contribut
entri
nativ
sar
explor
potenti
use
drug
prophylact
therapi
pretreat
human
airway
chip
perfus
vascular
channel
chloroquin
arbidol
toremifen
clomiphen
amodiaquin
verapamil
amiodaron
maximum
concentr
cmax
blood
report
human
tabl
mimic
system
distribut
oral
administr
hour
ad
airway
channel
continu
flow
drug
vascular
channel
addit
hour
studi
reveal
two
drug
amodiaquin
toremiphen
display
statist
signific
inhibit
viral
infect
clinic
relev
experiment
condit
fig
find
arbidol
significantli
inhibit
entri
human
airway
chip
administ
clinic
relev
dose
fig
wherea
effect
inhibitor
cell
static
condit
fig
consist
observ
arbidol
reliev
symptom
acceler
clearanc
nativ
viru
human
clinic
trial
interestingli
chloroquin
produc
statist
signific
inhibit
effect
administ
cmax
human
airway
chip
fig
lack
efficaci
chloroquin
seen
might
explain
observ
chloroquin
concentr
higher
level
lung
compar
blood
vivo
exert
therapeut
effect
human
mechan
block
viral
entri
howev
result
human
airway
chip
reminisc
find
indic
chloroquin
report
show
mild
therapeut
effect
preliminari
clinic
studi
small
number
patient
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
found
demonstr
signific
antivir
activ
studi
signific
toxic
observ
includ
preliminari
find
larger
random
doubleblind
phase
iib
clinic
trial
taken
togeth
data
show
human
lung
airway
chip
may
repres
humanrelev
preclin
tool
ad
current
arsen
assay
avail
virologist
drug
develop
confront
present
futur
viral
pandem
organ
chip
could
particularli
use
identifi
exist
approv
drug
may
repurpos
pandem
viru
applic
crisi
situat
face
today
requir
acceler
develop
potenti
therapeut
prophylact
intervent
exampl
work
repurpos
therapeut
initi
januari
one
day
sequenc
publish
first
result
drug
airway
chip
obtain
week
later
one
limit
human
organ
chip
rel
low
throughput
model
chip
run
per
autom
cultur
instrument
instrument
per
incub
take
week
differenti
airway
epithelium
ali
onchip
experi
initi
howev
level
mimicri
human
lung
physiolog
pathophysiolog
extrem
high
shown
previous
present
studi
variou
strain
infecti
influenza
viru
establish
cell
line
current
use
virolog
studi
cell
use
offer
higher
throughput
approach
rapid
screen
exhibit
featur
function
human
lung
epithelium
thu
effect
discoveri
pipelin
creat
combin
approach
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
abil
appli
drug
use
dynam
fluid
flow
also
enabl
cell
treat
clinic
relev
dynam
drug
exposur
administ
drug
cmax
compar
rel
potenc
anoth
caveat
quantifi
drug
absorpt
protein
bind
studi
importantli
carri
mass
spectrometri
measur
drug
level
devic
full
pk
profil
recapitul
organ
chip
model
aid
clinic
translat
futur
anim
model
remain
benchmark
valid
therapeut
move
human
import
note
result
anim
model
frequent
wrong
predict
drug
respons
human
clinic
trial
addit
human
organ
chip
shown
recapitul
drug
respons
toxic
observ
human
could
detect
anim
reason
regulatori
agenc
encourag
pharmaceut
biotechnolog
compani
make
use
data
organ
chip
microphysiolog
system
regulatori
submiss
studi
also
led
identif
multipl
approv
drug
could
serv
therapeut
prophylact
use
viral
pandem
anticoagul
drug
nafamostat
significantli
extend
treatment
time
window
oseltamivir
day
inocul
viru
could
great
clinic
relev
given
patient
begin
treatment
day
first
infect
interestingli
drug
found
inhibitor
pseudotyp
viru
infect
establish
cell
line
chloroquin
arbidol
toremifen
clomiphen
amodiaquin
verapamil
amiodaron
independ
shown
recent
other
also
inhibit
infect
vero
cell
nativ
viru
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respons
current
pandem
thu
least
context
pseudotyp
viru
gener
appear
reason
initi
assay
estim
effect
initi
viru
entri
cultur
cell
condit
howev
contrast
result
obtain
test
drug
pseudotyp
viru
group
observ
nativ
found
two
drug
amodiaquin
toremifen
prevent
infect
amodiaquin
antimalari
drug
relat
chloroquin
hydroxychloroquin
drug
decreas
entri
human
airway
cell
clinic
achiev
demonstr
plasma
patient
malaria
receiv
mg
administr
toremifen
select
estrogen
receptor
modul
also
current
clinic
develop
treatment
ebola
viru
infect
drug
approv
past
fda
applic
treatment
malaria
amodiaquin
metastat
breast
carcinoma
toremifen
distinct
therapeut
toxic
profil
make
less
attract
potenti
drug
treatment
amodiaquin
wide
use
past
prophylaxi
treatment
malaria
withdrawn
prophylact
use
due
rare
occurr
agranulocytosi
hepat
use
second
line
acut
treatment
p
falciparumresist
malaria
africa
combin
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
artesun
thu
amodiaquin
could
explor
nearterm
potenti
acut
therapeut
treatment
agent
nation
drug
readili
avail
may
particularli
valuabl
africa
low
resourc
nation
suppli
expens
altern
therapi
limit
toremifen
hand
shown
rel
well
toler
chronic
treatment
year
breast
cancer
male
well
femal
thu
could
consid
prophylaxi
treatment
given
alarm
rate
pandem
spread
clinician
serious
consid
rel
risk
benefit
use
exist
approv
drug
new
therapi
initi
trial
local
commun
current
pandem
past
one
caus
influenza
repres
immin
danger
major
ongo
public
health
concern
repurpos
exist
antivir
agent
use
multiplex
simpl
cellbas
assay
combin
lower
throughputhigh
content
human
organ
chip
recapitul
humanrelev
respons
rather
anim
model
often
faith
recapitul
human
symptom
could
provid
fast
track
potenti
treatment
current
pandem
equal
valuabl
unforeseen
biothreat
futur
multipl
recent
report
identifi
approv
drug
similarli
potenti
act
therapeut
howev
knowledg
none
recommend
base
result
respons
highli
differenti
human
lung
epitheli
cell
expos
drug
dynam
flow
condit
close
mimic
clinic
relev
blood
exposur
given
abil
recapitul
tissuetissu
interfac
recruit
circul
immun
cell
cytokin
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respons
mucociliari
clearanc
hostmicrobiom
interact
relev
human
organlevel
physiolog
behavior
vitro
perhap
greatest
valu
human
organ
chip
also
could
use
studi
humanrelev
immun
respons
infecti
viru
diseas
pathogenesi
difficult
replic
vitro
vivo
model
therefor
hope
move
technolog
laboratori
near
futur
similar
studi
carri
nativ
come
month
exist
approv
drug
found
activ
establish
cell
line
human
organ
chip
describ
potenti
could
use
prophylact
therapeut
influenza
infect
thu
also
might
consid
evalu
human
clinic
trial
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
coat
channel
wash
sequenti
buffer
pb
porou
membran
coat
side
collagen
type
iv
human
placenta
mgml
water
sigmaaldrich
room
temperatur
overnight
solut
aspir
chip
use
seed
cell
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
stemcel
supplement
vegf
egf
endotheli
cell
medium
kit
cell
biolog
bottom
vascular
channel
chip
cultur
incub
contain
humid
apic
surfac
epithelium
rins
weekli
pb
remov
cellular
debri
mucu
highli
differenti
human
airway
structur
function
maintain
human
lung
airway
chip
month
immunofluoresc
microscopi
cell
wash
pb
apic
basal
channel
fix
paraformaldehyd
alfa
aesar
min
wash
pb
store
c
fix
tissu
permeabil
onchip
triton
sigmaaldrich
pb
min
expos
pb
goat
serum
life
technolog
triton
min
room
temperatur
incub
primari
antibodi
supplementari
tabl
dilut
incub
buffer
pb
goat
serum
triton
overnight
c
follow
incub
correspond
secondari
antibodi
supplementari
tabl
h
room
temperatur
nuclei
counterstain
dapi
invitrogen
secondari
antibodi
stain
fluoresc
imag
carri
use
confoc
laserscan
microscop
x
mp
germani
imag
process
done
use
imari
softwar
bitplan
switzerland
measur
tissu
barrier
permeabl
cell
medium
contain
cascad
blue
da
invitrogen
ad
bottom
channel
cell
medium
ad
top
channel
fluoresc
intens
medium
top
bottom
channel
measur
h
later
three
differ
human
airway
chip
appar
permeabl
calcul
use
formula
papp
j
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
papp
appar
permeabl
j
molecular
flux
total
area
diffus
averag
gradient
infus
pb
upper
channel
airway
chip
incub
h
c
collect
fluid
store
c
analysi
previous
describ
quantif
mucu
product
carri
quantifi
alcian
blue
stain
thermo
fisher
scientif
compar
serial
dilut
standard
mucin
sigmaaldrich
pb
tabl
express
level
target
gene
normal
gapdh
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
analysi
neutrophil
infiltr
neutrophil
isol
fresh
human
blood
use
ficollpaqu
plu
ge
healthcar
gradient
resuspend
medium
concentr
cellsml
within
normal
rang
cellsml
neutrophil
found
human
blood
isol
neutrophil
label
immunofluoresc
microscop
analysi
carri
indic
time
plaqu
format
assay
viru
titer
determin
use
plaqu
format
assay
confluent
mdck
cell
monolay
plate
wash
pb
inocul
ml
serial
dilut
influenza
viru
sampl
incub
h
unabsorb
viru
remov
cell
monolay
overlaid
ml
dmem
gibco
supplement
low
melt
point
agaros
sigmaaldrich
tpcktreat
trypsin
sigmaaldrich
incub
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
day
cell
fix
paraformaldehyd
stain
crystal
violet
sigmaaldrich
visual
plaqu
viru
titer
determin
plaqueform
unit
per
millilit
pfuml
collect
analyz
panel
cytokin
chemokin
includ
rant
use
custom
procartaplex
assay
kit
invitrogen
analyt
concentr
determin
use
instrument
coupl
luminex
xponent
softwar
luminex
usa
incorpor
protein
confirm
use
western
blot
analysi
chimer
monoclon
antibodi
combin
constant
domain
human
molecul
mous
variabl
region
sinobiolog
recombin
receptor
bind
domain
rbd
fragment
region
use
control
bei
resourc
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
infect
assay
use
pseudotyp
virus
cell
drug
test
use
entri
assay
vsvpp
previous
describ
infect
perform
plate
vsvpp
ad
cell
human
liver
cell
line
per
well
presenc
absenc
test
drug
compound
mixtur
incub
hour
luciferas
activ
reflect
number
pseudoparticl
host
cell
measur
h
postinfect
use
brightglo
reagent
promega
accord
manufactur
instruct
test
drug
serial
dilut
final
concentr
maximum
infect
deriv
untreat
well
background
uninfect
well
calcul
infect
valu
luciferas
background
signal
subtract
intens
measur
well
expos
drug
valu
divid
averag
signal
measur
untreat
control
well
multipli
airway
chip
pseudotyp
viru
drug
flow
vascular
channel
airway
chip
report
cmax
human
blood
tabl
airway
channel
static
treat
concentr
drug
h
later
deliv
airway
channel
small
volum
medium
contain
drug
concentr
static
incub
addit
h
drug
dose
continu
flow
vascular
channel
lung
airway
epithelium
collect
rneasi
micro
kit
qiagen
accord
manufactur
instruct
subject
analysi
viral
load
qrtpcr
focus
assess
viral
entri
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
chip
line
differenti
airway
epithelium
contain
endothelium
specifi
least
three
chip
per
donor
use
experi
test
statist
signific
differ
group
perform
use
oneway
anova
newmankeul
multipl
comparison
test
differ
consid
signific
p
valu
less
p
p
p
ns
signific
result
express
mean
standard
deviat
sd
n
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
region
domain
rbd
fragment
use
posit
control
result
compar
cellular
gapdh
b
cell
infect
h
luciferas
activ
measur
estim
number
pseudoparticl
host
cell
pseudoparticl
without
spike
protein
use
control
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
treat
test
drug
h
cell
viabil
measur
celltiterglo
assay
cell
viabil
untreat
cell
set
note
none
drug
produc
signific
cytotox
dose
use
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
quiescent
endothelium
within
control
airway
chip
contain
airway
epithelium
opposit
side
porou
membran
endothelium
note
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
